These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 35802677

  • 1. DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome.
    Guidry K, Vasudevaraja V, Labbe K, Mohamed H, Serrano J, Guidry BW, DeLorenzo M, Zhang H, Deng J, Sahu S, Almonte C, Moreira AL, Tsirigos A, Papagiannakopoulos T, Pass H, Snuderl M, Wong KK.
    Clin Cancer Res; 2022 Sep 01; 28(17):3824-3835. PubMed ID: 35802677
    [Abstract] [Full Text] [Related]

  • 2. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.
    Ann Oncol; 2017 Jan 01; 28(1):75-82. PubMed ID: 27687306
    [Abstract] [Full Text] [Related]

  • 3. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A, Jönsson M, Lauss M, Brunnström H, Jönsson P, Borg Å, Jönsson G, Ringnér M, Planck M, Staaf J.
    Clin Cancer Res; 2014 Dec 01; 20(23):6127-40. PubMed ID: 25278450
    [Abstract] [Full Text] [Related]

  • 4. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C, Brodie SA, Palleschi A, Alloisio M, Pariscenti G, Jones K, Zhou W, Bouk AJ, Boland J, Hicks B, Risch A, Bennett H, Luke BT, Song L, Duan J, Liu P, Kohno T, Chen Q, Meerzaman D, Marconett C, Laird-Offringa I, Mills I, Caporaso NE, Gail MH, Pesatori AC, Consonni D, Bertazzi PA, Chanock SJ, Landi MT.
    PLoS Med; 2016 Dec 01; 13(12):e1002162. PubMed ID: 27923066
    [Abstract] [Full Text] [Related]

  • 5. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
    Wang P, Xu G, Gao E, Xu Y, Liang L, Jiang G, Duan L.
    Oxid Med Cell Longev; 2022 Dec 01; 2022():8802303. PubMed ID: 35814273
    [Abstract] [Full Text] [Related]

  • 6. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R.
    J Clin Oncol; 2021 Nov 20; 39(33):3747-3758. PubMed ID: 34591593
    [Abstract] [Full Text] [Related]

  • 7. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
    Xu F, He L, Zhan X, Chen J, Xu H, Huang X, Li Y, Zheng X, Lin L, Chen Y.
    Aging (Albany NY); 2020 Nov 21; 12(24):25275-25293. PubMed ID: 33234739
    [Abstract] [Full Text] [Related]

  • 8. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H, Zheng M, Shi M, Wang J, Huang Z, Zhang H, Zhou Y, Shi J.
    BMC Cancer; 2021 Aug 20; 21(1):938. PubMed ID: 34416861
    [Abstract] [Full Text] [Related]

  • 9. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
    Li H, Tong L, Tao H, Liu Z.
    Biosci Rep; 2020 Feb 28; 40(2):. PubMed ID: 32031203
    [Abstract] [Full Text] [Related]

  • 10. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H, Wei C, Pan P, Yuan F, Cheng J.
    Sci Rep; 2021 May 11; 11(1):9938. PubMed ID: 33976305
    [Abstract] [Full Text] [Related]

  • 11. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment.
    Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A.
    Lung Cancer; 2022 Oct 11; 172():19-28. PubMed ID: 35973335
    [Abstract] [Full Text] [Related]

  • 12. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
    Isaeva OI, Sharonov GV, Serebrovskaya EO, Turchaninova MA, Zaretsky AR, Shugay M, Chudakov DM.
    J Immunother Cancer; 2019 Oct 29; 7(1):279. PubMed ID: 31665076
    [Abstract] [Full Text] [Related]

  • 13. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
    Ke J, Cui J, Yang X, Du X, Ma B, Yu L.
    Zhongguo Fei Ai Za Zhi; 2022 May 20; 25(5):311-322. PubMed ID: 35599007
    [Abstract] [Full Text] [Related]

  • 14. Increased Tumor Intrinsic Growth Potential and Decreased Immune Function Orchestrate the Progression of Lung Adenocarcinoma.
    Zhao Y, Shang J, Gao J, Han H, Gao Z, Yan Y, Zheng Q, Ye T, Fu F, Deng C, Ma Z, Zhang Y, Zheng D, Zheng S, Li Y, Cao Z, Shi L, Chen H.
    Front Immunol; 2022 May 20; 13():921761. PubMed ID: 35844495
    [Abstract] [Full Text] [Related]

  • 15. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z, Li B, Guo Y, Wu L, Kou F, Yang L.
    Front Immunol; 2021 May 20; 12():723172. PubMed ID: 34539658
    [Abstract] [Full Text] [Related]

  • 16. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H, Liu SY, Zhou JY, Xu JT, Zhang HK, Yan HH, Huan JJ, Dai PP, Xu CR, Su J, Guan YF, Yi X, Yu RS, Zhong WZ, Wu YL.
    EBioMedicine; 2020 Oct 20; 60():102990. PubMed ID: 32927274
    [Abstract] [Full Text] [Related]

  • 17. Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma.
    Li D, Yu H, Hu J, Li S, Yan Y, Li S, Sun L, Jiang G, Hou L, Zhang L, Zhang P.
    J Transl Med; 2022 Sep 23; 20(1):423. PubMed ID: 36138435
    [Abstract] [Full Text] [Related]

  • 18. Necroptosis Identifies Novel Molecular Phenotypes and Influences Tumor Immune Microenvironment of Lung Adenocarcinoma.
    Zhao C, Xiong K, Adam A, Ji Z, Li X.
    Front Immunol; 2022 Sep 23; 13():934494. PubMed ID: 35911707
    [Abstract] [Full Text] [Related]

  • 19. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z, He B, Cai Q, Zhang P, Peng X, Zhang Y, Xie H, Wang X.
    Int Immunopharmacol; 2021 Sep 23; 98():107807. PubMed ID: 34175739
    [Abstract] [Full Text] [Related]

  • 20. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma.
    Liu K, Guo J, Liu K, Fan P, Zeng Y, Xu C, Zhong J, Li Q, Zhou Y.
    EBioMedicine; 2018 Oct 23; 36():196-208. PubMed ID: 30268834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.